基于ProMisE分类的108例子宫内膜癌分析及MMR-D基因检测
研究对108例子宫内膜癌患者应用ProMisE分类,通过p53/MMR免疫组化及POLE-EDM测序分为四个分子亚组,并对MMR-D病例深入检测体细胞或胚系遗传缺陷。结果显示ProMisE分类高效易行,MMR-D中MLH1启动子高甲基化为主要病因,部分病例存在多重分子特征。
要点
- ProMisE分类在子宫内膜癌中高效且易于实施。
- MMR-D病例中MLH1启动子高甲基化是主要病因。
- 多重分子特征病例的生物学和预后意义需进一步研究。
核心结论
- ProMisE分类被证明是高效且易于实施的系统。
- 未来研究应阐明具有多重分子标记病例的精确生物学和预后意义。
研究设计与样本
- 连续纳入2017年3月至2019年4月诊断的108例子宫内膜癌患者,进行免疫组化和分子分析。
- 采用p53和错配修复蛋白(MLH1、PMS2、MSH6和PMS2)免疫组化,所有患者行POLE-EDM的Sanger测序。
- 对MMR免疫组化异常病例的肿瘤和正常组织行PCR微卫星不稳定性检测,并用甲基化特异性多重连接依赖探针扩增检测MLH1启动子高甲基化。
- MMR-D病例行错配修复基因胚系突变分析,包括二代测序、RNA突变分析和MLPA。
主要发现
- FIGO分期为IA期54例、IB期22例、II期8例、III期18例、IV期6例。
- 免疫组化MMR-D患者33例(31%),其中26例显示MLH1启动子高甲基化作为MMR-D的可能原因。
- 剩余7例无MLH1启动子高甲基化的患者转诊进行Lynch综合征胚系分析,6例携带错配修复基因致病性胚系突变:MSH6(3例)、PMS2(1例)、MLH1(1例)和MSH2(1例)。
- 7例(6%)患者鉴定出致病性POLE-EDM。
- 4例(4%)患者观察到多重分子特征(POLE-EDM+MMR-D或POLE-EDM+p53异常)。
临床怎么用
- ProMisE分类可应用于子宫内膜癌的分子分型,便于临床实施。
- 对MMR-D病例应检测MLH1启动子高甲基化以区分散发性与Lynch综合征。
- 无MLH1启动子高甲基化的MMR-D病例应转诊进行Lynch综合征胚系分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To apply the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to a consecutive series of endometrial cancer (EC) patients diagnosed at a tertiary referral center and assign EC specimens to one of four molecular subgroups using immunohistochemistry (IHC) for p53/mismatch repair protein expression and sequencing for Polymerase Epsilon Exonuclease Domain Mutations (POLE-EDM). Mismatch Repair Deficient (MMR-D) cases were more thoroughly investigated to identify underlying somatic or germline genetic defects. METHODS: Hundred-and eight consecutive endometrial cancer patients, diagnosed between March 2017 and April 2019, were subjected to immunohistochemical and molecular analysis, according to ProMisE. IHC for p53 and the mismatch repair proteins (MLH1, PMS2, MSH6 and PMS2) was performed. All patients were also tested for POLE-EDM by Sanger sequencing. In addition, tumor and corresponding normal tissue of cases with abnormal MMR IHC were tested by PCR for microsatellite instability (MSI) (MSI analysis system, Promega). Hypermethylation of MLH1 promotor was tested with (methylation specific) multiplex ligation dependent probe amplification. MMR-D cases were subjected to germline mutation analysis of the mismatch repair genes, using next generation sequencing on MiSeq (Illumina) with the BRCA Hereditary Cancer MASTR Plus, (Multiplicom/Agilent), RNA mutation analysis and MLPA. RESULTS: FIGO classification was stage IA (n = 54), IB (n = 22) II(n = 8), III(n = 18) and IV(n = 6). Of the 33 patients with MMR-D on IHC (31%), 26 showed MLH1 promotor hypermethylation as the probable cause of MMR-D. The remaining 7 patients without MLH1 promotor hypermethylation were referred for germline analysis of Lynch syndrome. Six patients carried a pathogenic germline mutation in one of the mismatch repair genes: MSH6(n = 3), PMS2(n = 1), MLH1(n = 1) and MSH2 (n = 1). Pathogenic POLE-EDM were identified in 7 (6%) patients. Multiple molecular features (POLE-EDM + MMR-D or POLE-EDM + p53 abnormal) were observed in 4 patients (4%). A high concordance between MMR-D and microsatellite instability was observed in our cohort. In cases of a genetic defect in the MMR genes, we do note a large proportion of cases exhibiting microsatellite instability. On the contrary a hypermutation state, as seen in POLE EDM, does not result in accompanied phenotypic changes in MSI status. CONCLUSION: The ProMisE classification proved to be an efficient and easily implementable system. Future research should elucidate the precise biological and prognostic meaning of the cases with multiple molecular markers.
引用
- Timmerman S, Van Rompuy AS, Van Gorp T, et al. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. Gynecol Oncol. 2020. PMID: 31980219. doi:10.1016/j.ygyno.2020.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。